GlassScriptPhysician profile
Thu-Ba Leba
NPI 1366633554
$5,358.09
in general payments reported to CMS, 2019-2025
12 companies · $14.45 in 2025
The $14.45 reported for 2025 was less than what a typical Pediatric Orthopaedic Surgery provider received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,276 · 2020: $3,036 · 2021: $24.66 · 2022: $38.57 · 2023: $66.46 · 2024: $902 · 2025: $14.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $717 · Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $716.91 |
| Food and Beverage | $265.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequoia Surgical, INC. | $2,697.79 | 2020 | |
| Stryker Corporation | $1,154.91 | 2019-2024 | |
| Cornerstone Medical Associates, INC. | $600.03 | 2023-2024 | |
| Zimmer Biomet Holdings, INC. | $477.57 | 2019 | |
| Arthrex, INC. | $224.95 | 2024 | |
| Biomarin Pharmaceutical INC. | $63.23 | 2021-2022 | |
| Ethicon US, LLC | $44.03 | 2024 | Stratafix, Ethicon, Megadyne |
| Medtronic, INC. | $31.09 | 2024 | O-Arm |
| Ultragenyx Pharmaceutical INC. | $18.98 | 2023 | |
| Bioventus LLC | $17.58 | 2023 | Exogen Ultrasound Bone Healing System |
| Solventum Corporation | $14.45 | 2025 | Prevena |
| Masimo Corporation | $13.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thu-Ba Leba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.